Patient-reported outcomes of patients with advanced renal cell carcinoma (aRCC) treated with first-line nivolumab plus cabozantinib versus sunitinib: The CheckMate 9ER trial.

被引：11
|
作者：
Cella, David [1 ]
Choueiri, Toni K. [2 ]
Blum, Steven, I [3 ]
Ejzykowicz, Flavia [3 ]
Hamilton, Melissa [3 ]
Zhang, Joshua [3 ]
Ivanescu, Cristina [4 ]
Motzer, Robert J. [5 ]
机构：
[1] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[2] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] IQVIA, Herikerbergweg, Netherlands
[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.285
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
285
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Nivolumab plus cabozantinib (N plus C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial
    Bourlon, Maria Teresa
    Escudier, Bernard
    Burotto, Mauricio
    Powles, Thomas
    Apolo, Andrea B.
    Shah, Amishi Yogesh
    Porta, Camillo
    Suarez, Cristina
    Barrios, Carlos H.
    Richardet, Martin
    Gurney, Howard
    Kessler, Elizabeth R.
    Tomita, Yoshihiko
    Bedke, Jens
    Wang, Fong
    Wang, Peter
    Panzica, Julie
    Fedorov, Viktor
    Motzer, Robert J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 362 - 362
  • [22] Nivolumab plus cabozantinib (NIVO plus CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER.
    Motzer, Robert J.
    Choueiri, Toni K.
    Powles, Thomas
    Burotto, Mauricio
    Bourlon, Maria Teresa
    Hsieh, James J.
    Maruzzo, Marco
    Shah, Amishi Yogesh
    Suarez, Cristina
    Barrios, Carlos H.
    Richardet, Martin Eduardo
    Porta, Camillo
    Goh, Jeffrey C.
    Tomita, Yoshihiko
    Bedke, Jens
    Zhang, Joshua
    Simsek, Burcin
    Scheffold, Christian
    Gupta, Saurabh
    Apolo, Andrea B.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [23] Cost-effectiveness analysis of nivolumab plus cabozantinib versus sunitinib as first-line therapy in advanced renal cell carcinoma
    Liu, Ruizhe
    Qiu, Kaifeng
    Wu, Junyan
    Jiang, Yanqing
    Wu, Peihao
    Pang, Jianxin
    IMMUNOTHERAPY, 2022, 14 (11) : 859 - 869
  • [24] Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial (vol 20, pg 297, 2019)
    Cella, D.
    Grunwald, V
    Escudier, B.
    LANCET ONCOLOGY, 2019, 20 (06): : E293 - E293
  • [25] Nivolumab Plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma (aRCC): 3-Year Follow-Up From the Phase 3 CheckMate 9 ER Trial (vol 41, pg 603, 2023)
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (21) : 3767 - 3767
  • [26] Increasing combination possibilities for first-line treatment of metastatic clear cell renal cell carcinoma with nivolumab plus cabozantinib Results of the CheckMate-9ER trial
    Oing, Christoph
    Bokemeyer, Carsten
    ONKOLOGE, 2021, 27 (02): : 168 - 171
  • [27] Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States
    Li, SiNi
    Li, JianHe
    Peng, LiuBao
    Li, YaMin
    Wan, XiaoMin
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [28] Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial
    Apolo, Andrea B.
    Powles, Thomas
    Escudier, Bernard
    Burotto, Mauricio
    Zhang, Joshua
    Simsek, Burcin
    Scheffold, Christian
    Motzer, Robert J.
    Choueiri, Toni K.
    EUROPEAN JOURNAL OF CANCER, 2022, 177 : 63 - 71
  • [29] Advanced Renal Cell Carcinoma Cabozantinib plus Nivolumab: New First-Line Standard?
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (06) : 362 - 363
  • [30] Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial (vol 23, pg 888, 2022)
    Motzer, R. J.
    Powles, T.
    Burotto, M.
    LANCET ONCOLOGY, 2022, 23 (07): : E319 - E319
12345